TY  - GEN
AU  - Garcia-Donas, Jesus
AU  - Hurtado, Alicia
AU  - Garrigos, Laia
AU  - Santaballa, Ana
AU  - Redondo, Andres
AU  - Vidal, Laura
AU  - Lainez, Nuria
AU  - Guerra, Eva
AU  - Rodriguez, Victor
AU  - Cueva, Juan
AU  - Bover, Isabel
AU  - Palacio, Isabel
AU  - Rubio, Maria Jesus
AU  - Prieto, Mario
AU  - Lopez-Guerrero, Jose Antonio
AU  - Rodriguez-Moreno, Juan Francisco
AU  - Garcia-Casado, Zaida
AU  - Garcia-Martinez, Elena
AU  - Taus, Alvaro
AU  - Perez de Castro, Ignacio
AU  - Navarro, Paloma
AU  - Grande, Enrique
AU  - Spanish Group for Research in Orphan, Infrequent Tumors (GETHI)
PY  - 2023
DO  - 10.1007/s12094-023-03085-w
SN  - 1699-048X
UR  - https://hdl.handle.net/20.500.12105/26044
AB  - Background: Granulosa cell ovarian tumor (GCT) is characterized by a pathognomonic mutation in the FOXL2 gene (402 C > G) that leads to an overactivation of steroidogenesis. CYP17 is a key enzyme in such process and can be inhibited by ketoconazole....
LA  - eng
PB  - Springer
KW  - Granulosa cell ovarian cancer
KW  - Hormonetherapy
KW  - Ketoconazole
KW  - Enzyme Inhibitors
KW  - Female
KW  - Forkhead Transcription Factors
KW  - Granulosa Cell Tumor
KW  - Granulosa Cells
KW  - Humans
KW  - Ketoconazole
KW  - Ovarian Neoplasms
KW  - Steroid 17-alpha-Hydroxylase
TI  - Open-label phase II clinical trial of ketoconazole as CYP17 inhibitor in metastatic or advanced non-resectable granulosa cell ovarian tumors: the GREKO (GRanulosa Et KetOconazole) trial, GETHI 2011-03
TY  - research article
ER  -